Ceftobiprole meets Phase III CAP endpoint

Basilea (SWX:BSLN) said ceftobiprole ( BAL5788) met the primary endpoint of non-inferiority vs. ceftriaxone alone or in combination with linezolid in a Phase III trial to treat community acquired pneumonia (CAP) in patients requiring hospitalization. The clinical cure rate in evaluable patients was 86% for ceftobiprole vs. 87% for the comparator arms. The microbiological eradication rates were 88% in ceftobiprole patients and 92% in the comparator groups. In patients with moderate to severe pneumonia, the clinical cure rate was 89% for ceftobiprole and 81% for the comparator arms. BSLN granted Johnson & Johnson (JNJ) worldwide rights to the broad spectrum anti-MRSA cephalosporin antibiotic that inhibits penicillin-binding proteins (PBP) in 2005 (See BioCentury Extra, Thursday, Feb. 03, 2005). ...